Literature DB >> 27573202

Glycated albumin indicates peripheral diabetic neuropathy.

Nana Wang1, Chuanji Guo2, Ping Han1, Tiegang Li3.   

Abstract

AIMS: We investigated associations between serum levels of glycated albumin (GA) and glycated hemoglobin (HbA1c) and the presence of diabetic peripheral neuropathy (DPN) in patients with type 1 diabetes mellitus (T1DM).
METHODS: Between September 2009 and April 2015, we evaluated 314 patients with T1DM in the Endocrinology Department of Shengjing Hospital of China Medical University. We divided the patients into the DPN group (n = 72) and the non-DPN group (n = 242), on the basis of the presence of DPN.
RESULTS: The DPN group had significantly higher GA values than the non-DPN group. After univariate logistic regression, we selected several factors for further analysis: HbA1c, GA, duration of T1DM, body mass index, smoking, hypertension, and the presence of diabetic complications, including nephropathy, retinopathy, and cardiovascular disease. We performed a multivariate logistic regression analysis to examine the association between the presence of DPN and each of these variables. We identified GA, HbA1c, hypertension, smoking, retinopathy, and cardiovascular disease as independent variables for indicating the presence of DPN. Results of a receiver operating characteristic curve analysis revealed that the area under the curve of GA (0.771) was larger than that of HbA1c (0.629). We defined the cutoff value of GA as 23.5 % (sensitivity 0.764, specificity 0.661) and the cutoff value of HbA1c as 8.45 % (sensitivity 0.667, specificity 0.595) for predicting DPN in patients with T1DM.
CONCLUSIONS: GA may be a better indicative marker of DPN in patients with T1DM than HbA1c.

Entities:  

Keywords:  Diabetic peripheral neuropathy; Glycated albumin; Hemoglobin A1c; Type 1 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 27573202     DOI: 10.1007/s00592-016-0900-y

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  6 in total

1.  Glycated albumin and HbA1c as markers of lower extremity disease inUS adults with and without diabetes.

Authors:  Caitlin W Hicks; Dan Wang; Kunihiro Matsushita; John W McEvoy; Robert Christenson; Elizabeth Selvin
Journal:  Diabetes Res Clin Pract       Date:  2022-01-20       Impact factor: 5.602

2.  HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients.

Authors:  Jian-Bin Su; Li-Hua Zhao; Xiu-Lin Zhang; Hong-Li Cai; Hai-Yan Huang; Feng Xu; Tong Chen; Xue-Qin Wang
Journal:  Cardiovasc Diabetol       Date:  2018-03-29       Impact factor: 9.951

3.  Protein pyrrole adducts are associated with elevated glucose indices and clinical features of diabetic diffuse neuropathies.

Authors:  Xiao Chen; Zhuyi Jiang; Lianjing Zhang; Wei Liu; Xiaohu Ren; Luling Nie; Desheng Wu; Zhiwei Guo; Weimin Liu; Xifei Yang; Yan Wu; Zhen Liang; Peter Spencer; Jianjun Liu
Journal:  J Diabetes       Date:  2022-10-04       Impact factor: 4.530

4.  Glycated albumin and its variability as an indicator of cardiovascular autonomic neuropathy development in type 2 diabetic patients.

Authors:  Ji Eun Jun; Seung-Eun Lee; You-Bin Lee; Ji Yeon Ahn; Gyuri Kim; Sang-Man Jin; Kyu Yeon Hur; Moon-Kyu Lee; Jae Hyeon Kim
Journal:  Cardiovasc Diabetol       Date:  2017-10-10       Impact factor: 9.951

5.  NOD Mice-Good Model for T1D but Not Without Limitations.

Authors:  Virginia R Aldrich; Barbara B Hernandez-Rovira; Ankit Chandwani; Midhat H Abdulreda
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 6.  Redefining distal symmetrical polyneuropathy features in type 1 diabetes: a systematic review.

Authors:  Eleonora Galosi; Xiaoli Hu; Nivatha Michael; Jens Randel Nyengaard; Andrea Truini; Páll Karlsson
Journal:  Acta Diabetol       Date:  2021-07-02       Impact factor: 4.280

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.